SequelSEC

BIOVIE INC. BIVI

Pharmaceutical Preparations · CIK 0001580149 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2016-09-30
Operating income
-$351.35K
Fiscal year ended 2016-09-30
Free cash flow
Unavailable
Fiscal year ended 2016-09-30

Valuation, from the filing

Public float$8.45MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-12-31
Float per share$1.12Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2026-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio3.59x48th

BIOVIE INC. (BIVI) reported revenue of $0 and net income of -$351.34K for the fiscal year ended 2016-09-30. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from BIOVIE INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BIOVIE INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302015-09-30
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Operating income-$351.35K-$54.63K
Net income-$351.34K-$54.57K
Research & development$127.27K$0
Weighted-average diluted sharesUnavailableUnavailable
Pretax incomeUnavailableUnavailable
Income tax expense$0$0
Diluted EPSUnavailableUnavailable
Selling, general & administrative$2.23K$3.30K
General & administrativeUnavailableUnavailable
Selling & marketingUnavailableUnavailable

Balance

BIOVIE INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302015-09-30
Cash & equivalentsUnavailableUnavailable
Total assets$2.54M$266.02K
Current assets$8.74K$266.02K
Total liabilitiesUnavailableUnavailable
Current liabilities$961.40K$372.81K
Total equity incl. NCI$1.58M-$106.80K
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
Goodwill$345.71KUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$381.29K$9.49K

Cash flow

BIOVIE INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302015-09-30
Operating cash flow-$128.01K-$1.96K
Capital expendituresUnavailableUnavailable
Investing cash flow$0$0
Financing cash flow$13.00K$0
Net change in cash-$115.01K-$1.96K
Stock-based compensationUnavailableUnavailable
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

BIOVIE INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302015-09-30
Free cash flowUnavailableUnavailable
Gross marginUnavailableUnavailable
Operating marginUnavailableUnavailable
FCF marginUnavailableUnavailable
SBC / revenueUnavailableUnavailable
Current ratio0.01x0.71x
Revenue YoY growthUnavailableUnavailable
Net marginUnavailableUnavailable
R&D / revenueUnavailableUnavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIVI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-Q · Filed 2026-02-06View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-K · Filed 2025-08-15View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.